Last reviewed · How we verify
NCT03229031
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury
Phase 3 trial testing ES135 in Spinal Cord Injuries in 160 participants. Suspended.
31 December 2024
Quick facts
| Lead sponsor | Eusol Biotech Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 7 March 2018 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2026 |
| Sites | 3 locations across Taiwan |
Drugs / interventions tested
- ES135 — full drug profile →
Conditions studied
- Spinal Cord Injuries — all drugs for Spinal Cord Injuries →
Sponsor
Eusol Biotech Co., Ltd. — full company profile →
Who can join
Adults 15 to 65, any sex, with Spinal Cord Injuries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To demonstrate the superior effect of ES135 combined with spinal cord repairing surgery, compared to a placebo control with spinal cord repairing surgery, on post-surgery motor function recovery as measured by the changes from baseline of ISNCSCI Motor Scores in subjects
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Fibroblast growth factor signaling in axons: from development to disease.
Tomé D, Dias MS, Correia J, Almeida RD. · · 2023 · cited 22× · PMID 37845690 · DOI 10.1186/s12964-023-01284-0 -
Established and Emerging Therapies in Acute Spinal Cord Injury.
Gadot R, Smith DN, Prablek M, Grochmal JK, et al · · 2022 · cited 19× · PMID 35793931 · DOI 10.14245/ns.2244176.088 -
Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor.
Ko CC, Tu TH, Wu JC, Huang WC, et al · · 2018 · cited 19× · PMID 30139947 · DOI 10.1038/s41598-018-31083-4 -
Combining Therapeutic Strategies to Treat the Injured Spinal Cord: A Translational Perspective.
Sherman BC, Schmidt Read M, Hoh DJ, Guest JD, et al · · 2025 · cited 2× · PMID 40929022 · DOI 10.1177/08977151251371710
Verify or expand the search:
- PubMed search for NCT03229031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spinal Cord Injuries
Currently open trials in the same condition.
- NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury · NA · recruiting
- NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial · NA · recruiting
- NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury · NA · recruiting
- NCT07488793 — Remote Ischemic Conditioning for PwSCI · NA · recruiting
- NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03229031 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eusol Biotech Co., Ltd.
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03229031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing